Development and Evaluation of a Nanoformulated Drug Delivery System for Enhanced Bioavailability of a Poorly Water-Soluble Anticancer Agent

Project Abstract

This study focuses on the development and comprehensive evaluation of a nanoformulated drug delivery system aimed at enhancing the bioavailability of a poorly water-soluble anticancer agent. The hydrophobic nature of many anticancer drugs often limits their therapeutic efficacy due to poor solubility and low absorption rates, necessitating the formulation of innovative delivery systems. In this research, nanoparticles were synthesized using a combined method of solvent evaporation and emulsification, employing biocompatible polymers such as poly(lactic-co-glycolic acid) (PLGA). The formulation process involved optimizing parameters such as polymer concentration, surfactant type, and stirring speed to produce nanoparticles with desirable characteristics. The resulting nanoparticles were characterized extensively through particle size analysis, zeta potential measurement, drug loading efficiency, and encapsulation efficiency using dynamic light scattering (DLS), electron microscopy, and spectroscopic methods. The in vitro drug release profile was evaluated in simulated physiological conditions to determine the sustained release capacity of the nanoformulation. Additionally, the stability of nanoparticles under different storage conditions was assessed over time to ensure shelf life viability. Furthermore, in vitro cytotoxicity studies were conducted on relevant cancer cell lines to compare the efficacy of the nanoformulated drug against free drug controls, revealing significantly enhanced cellular uptake and cytotoxicity with the nanoformulation. Pharmacokinetic studies in animal models demonstrated a marked increase in bioavailability, characterized by higher plasma concentration levels and extended half-life, suggesting improved absorption and retention. Biodistribution studies illustrated preferential accumulation of nanoparticles within tumor tissues due to the enhanced permeation and retention (EPR) effect, which is critical for targeted therapy. The safety profile was confirmed through histopathological examinations of major organs, revealing no significant toxicity attributable to the nanoformulation. This research underscores the potential of nanoencapsulation techniques in overcoming solubility challenges associated with hydrophobic anticancer agents, ultimately improving therapeutic outcomes and reducing systemic side effects. The study also discusses the scalability of the nanoformulation process, regulatory considerations, and future prospects for clinical translation. The findings provide valuable insights into the design of effective nanoparticulate systems for cancer therapy, emphasizing the importance of physicochemical optimization, quality control, and targeted delivery in developing next-generation anticancer drugs. Overall, this work contributes to the growing field of nanomedicine, presenting a promising approach to enhance the efficacy and safety of poorly water-soluble chemotherapeutic agents.

Project Overview

This project is about creating a special delivery system that uses tiny particles, called nanoparticles, to help deliver an anticancer drug more effectively in the body. The main problem it addresses is that some powerful anticancer medicines do not dissolve well in water, which makes it hard for the body to absorb and use them properly. Because of this, patients might need higher doses, which can cause more side effects, or the drug might not work as well as it should. The goal of the project is to develop a way to package the drug into these tiny particles so it can be absorbed better, making it more effective at fighting cancer and reducing side effects. The researcher will start by studying the properties of the anticancer agent, understanding how it behaves alone, and what makes it poorly water-soluble. Next, they will design a method to turn the drug into nano-sized particles, often with special materials that make the drug dissolve and spread in the body more easily. After creating these nanoformulations, the researcher will test them in the lab to see how well the drug dissolves and how stable the tiny particles are over time. Following this, experiments will be conducted to test how the new system behaves in biological systems, including how much of the drug enters the bloodstream and how long it stays active. Finally, the researcher will compare their new formulation to the traditional drug to see if it provides better absorption and effectiveness. The expected outcome of this project is a new nano-based delivery system that significantly improves how well the anticancer drug is absorbed and utilized by the body. This could lead to more effective cancer treatments with fewer side effects, making the medication safer and more efficient for patients. The project will also contribute valuable knowledge about designing nano-sized drug carriers for other poorly soluble medicines in the future.